Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
M.D. Anderson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Children's Hospital of Philadelphia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Center for International Blood and Marrow Transplant Research
Wake Forest University Health Sciences
Mayo Clinic
St. Jude Children's Research Hospital
University of Florida
Janssen Research & Development, LLC
Janssen Research & Development, LLC
University of Miami
Beijing Biotech
PedAL BCU, LLC
Children's Oncology Group
Dana-Farber Cancer Institute
St. Justine's Hospital
University of Colorado, Denver
Alliance for Clinical Trials in Oncology
University of Arizona
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
CRISPR Therapeutics
University of Chicago
City of Hope Medical Center
Children's Oncology Group
University of Kansas Medical Center
Sumitomo Pharma America, Inc.
AbbVie
The First Affiliated Hospital of Soochow University
The Children's Hospital of Zhejiang University School of Medicine
City of Hope Medical Center
Syndax Pharmaceuticals
CareDx
Center for International Blood and Marrow Transplant Research
M.D. Anderson Cancer Center
AstraZeneca
MEI Pharma, Inc.
Center for International Blood and Marrow Transplant Research
Sellas Life Sciences Group
AvenCell Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Gyala Therapeutics